Brief: Mirage Phase Iii Randomized Controlled Trial Demonstrates Superiority Of Mridian® Mri-Guidance In Stereotactic Body Radiotherapy (Sbrt) For Localized Prostate Cancer
27/10/2022 11:35
Oct 27 (Reuters) - ViewRay Inc VRAY.O :
* MIRAGE PHASE III RANDOMIZED CONTROLLED TRIAL DEMONSTRATES
SUPERIORITY OF MRIDIAN® MRI-GUIDANCE IN STEREOTACTIC BODY
RADIOTHERAPY (SBRT) FOR LOCALIZED PROSTATE CANCER
Source text for Eikon: ID:nPn19c3Rya
Further company coverage: VRAY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Viewray
See all newsBrief: ViewRay Announces Commencement Of Nasdaq Delisting Proceedings Common Stock Expected To Begin Trading On The OTC Markets
Press Digest: Wall Street Journal - July 18
U.S. STOCKS ON THE MOVE-Argenx, ViewRay, Ford
ViewRay hits record low on filing for voluntary Chapter 11 bankruptcy
U.S. STOCKS ON THE MOVE-Activision Blizzard, Tesla, Paramount Global